218 related articles for article (PubMed ID: 18181689)
1. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.
Sharlow ER; Leimgruber S; Shun TY; Lazo JS
Assay Drug Dev Technol; 2007 Dec; 5(6):723-35. PubMed ID: 18181689
[TBL] [Abstract][Full Text] [Related]
2. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer.
Kim TG; Lee JH; Lee MY; Kim KU; Lee JH; Park CH; Lee BH; Oh KS
Biol Pharm Bull; 2017; 40(9):1454-1462. PubMed ID: 28867728
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen.
Tanaka K; Koresawa M; Iida M; Fukasawa K; Stec E; Cassaday J; Chase P; Rickert K; Hodder P; Takagi T; Komatani H
Assay Drug Dev Technol; 2010 Feb; 8(1):47-62. PubMed ID: 20085455
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
6. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
[TBL] [Abstract][Full Text] [Related]
9. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
10. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.
Abdelfatah S; Fleischer E; Klinger A; Wong VKW; Efferth T
Invest New Drugs; 2020 Feb; 38(1):1-9. PubMed ID: 30877426
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.
Shin SB; Woo SU; Lee YJ; Yim H
Anticancer Res; 2017 Mar; 37(3):1177-1183. PubMed ID: 28314279
[TBL] [Abstract][Full Text] [Related]
12. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.
Normandin K; Lavallée JF; Futter M; Beautrait A; Duchaine J; Guiral S; Marinier A; Archambault V
Sci Rep; 2016 Nov; 5():37581. PubMed ID: 27874094
[TBL] [Abstract][Full Text] [Related]
13. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
Lu J; Xin S; Meng H; Veldman M; Schoenfeld D; Che C; Yan R; Zhong H; Li S; Lin S
PLoS One; 2013; 8(4):e53317. PubMed ID: 23658603
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.
Yun T; Qin T; Liu Y; Lai L
ChemMedChem; 2016 Apr; 11(7):713-7. PubMed ID: 27061239
[TBL] [Abstract][Full Text] [Related]
16. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
[TBL] [Abstract][Full Text] [Related]
17. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
19. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
20. A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Methods Mol Biol; 2012; 795():69-81. PubMed ID: 21960216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
